Bioteque (4107) - Net Assets
Based on the latest financial reports, Bioteque (4107) has net assets worth NT$3.61 Billion TWD (≈ $113.65 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$4.66 Billion ≈ $146.82 Million USD) and total liabilities (NT$1.05 Billion ≈ $33.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Bioteque to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$3.61 Billion |
| % of Total Assets | 77.41% |
| Annual Growth Rate | 8.4% |
| 5-Year Change | 28.68% |
| 10-Year Change | 73.64% |
| Growth Volatility | 11.51 |
Bioteque - Net Assets Trend (2006–2025)
This chart illustrates how Bioteque's net assets have evolved over time, based on quarterly financial data. See Bioteque defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Bioteque (2006–2025)
The table below shows the annual net assets of Bioteque from 2006 to 2025. For live valuation and market cap data, see 4107 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$3.61 Billion ≈ $113.65 Million |
+4.83% |
| 2024-12-31 | NT$3.44 Billion ≈ $108.41 Million |
+7.86% |
| 2023-12-31 | NT$3.19 Billion ≈ $100.51 Million |
+5.22% |
| 2022-12-31 | NT$3.03 Billion ≈ $95.52 Million |
+8.16% |
| 2021-12-31 | NT$2.80 Billion ≈ $88.32 Million |
+5.22% |
| 2020-12-31 | NT$2.66 Billion ≈ $83.94 Million |
+7.08% |
| 2019-12-31 | NT$2.49 Billion ≈ $78.39 Million |
+7.52% |
| 2018-12-31 | NT$2.31 Billion ≈ $72.90 Million |
+8.30% |
| 2017-12-31 | NT$2.14 Billion ≈ $67.32 Million |
+2.86% |
| 2016-12-31 | NT$2.08 Billion ≈ $65.45 Million |
+9.47% |
| 2015-12-31 | NT$1.90 Billion ≈ $59.79 Million |
+0.85% |
| 2014-12-31 | NT$1.88 Billion ≈ $59.28 Million |
+16.45% |
| 2013-12-31 | NT$1.62 Billion ≈ $50.91 Million |
+25.89% |
| 2012-12-31 | NT$1.28 Billion ≈ $40.44 Million |
+3.44% |
| 2011-12-31 | NT$1.24 Billion ≈ $39.10 Million |
-0.18% |
| 2010-12-31 | NT$1.24 Billion ≈ $39.17 Million |
-0.77% |
| 2009-12-31 | NT$1.25 Billion ≈ $39.47 Million |
+5.62% |
| 2008-12-31 | NT$1.19 Billion ≈ $37.37 Million |
+1.15% |
| 2007-12-31 | NT$1.17 Billion ≈ $36.95 Million |
+50.63% |
| 2006-12-31 | NT$778.61 Million ≈ $24.53 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bioteque's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2063.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$1.97 Billion | 54.56% |
| Other Components | NT$1.64 Billion | 45.44% |
| Total Equity | NT$3.61 Billion | 100.00% |
Bioteque Competitors by Market Cap
The table below lists competitors of Bioteque ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HUA YU LIEN Development Co Ltd
TW:1436
|
$254.37 Million |
|
Hold-Key Electric Wire & Cable Co Ltd
TW:1618
|
$254.37 Million |
|
Y.U.D. Yangtze River Investment Industry Co Ltd
SHG:600119
|
$254.42 Million |
|
Greenpanel Industries Limited
NSE:GREENPANEL
|
$254.49 Million |
|
Erdene Resource Development Corp
TO:ERD
|
$254.30 Million |
|
Sirca Paints India Limited
NSE:SIRCA
|
$254.18 Million |
|
Socep Constant
RO:SOCP
|
$254.12 Million |
|
Platinum Asia Investments Ltd
AU:PAI
|
$254.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bioteque's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,440,970,000 to 3,607,172,000, a change of 166,202,000 (4.8%).
- Net income of 539,185,000 contributed positively to equity growth.
- Dividend payments of 346,492,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$539.18 Million | +14.95% |
| Dividends Paid | NT$346.49 Million | -9.61% |
| Other Changes | NT$-26.49 Million | -0.73% |
| Total Change | NT$- | 4.83% |
Book Value vs Market Value Analysis
This analysis compares Bioteque's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.24x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 11.47x to 2.24x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | NT$10.16 | NT$116.50 | x |
| 2007-12-31 | NT$14.87 | NT$116.50 | x |
| 2008-12-31 | NT$14.85 | NT$116.50 | x |
| 2009-12-31 | NT$15.69 | NT$116.50 | x |
| 2010-12-31 | NT$15.58 | NT$116.50 | x |
| 2011-12-31 | NT$15.48 | NT$116.50 | x |
| 2012-12-31 | NT$16.27 | NT$116.50 | x |
| 2013-12-31 | NT$20.04 | NT$116.50 | x |
| 2014-12-31 | NT$21.52 | NT$116.50 | x |
| 2015-12-31 | NT$24.18 | NT$116.50 | x |
| 2016-12-31 | NT$29.82 | NT$116.50 | x |
| 2017-12-31 | NT$30.71 | NT$116.50 | x |
| 2018-12-31 | NT$33.22 | NT$116.50 | x |
| 2019-12-31 | NT$35.75 | NT$116.50 | x |
| 2020-12-31 | NT$38.28 | NT$116.50 | x |
| 2021-12-31 | NT$40.28 | NT$116.50 | x |
| 2022-12-31 | NT$43.53 | NT$116.50 | x |
| 2023-12-31 | NT$45.82 | NT$116.50 | x |
| 2024-12-31 | NT$49.65 | NT$116.50 | x |
| 2025-12-31 | NT$52.05 | NT$116.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bioteque utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.95%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 25.25%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.29x
- Recent ROE (14.95%) is below the historical average (15.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 7.36% | 11.64% | 0.38x | 1.68x | NT$-20.59 Million |
| 2007 | 26.36% | 55.20% | 0.34x | 1.41x | NT$191.87 Million |
| 2008 | 14.45% | 26.18% | 0.38x | 1.45x | NT$52.83 Million |
| 2009 | 12.65% | 20.32% | 0.45x | 1.38x | NT$33.23 Million |
| 2010 | 13.88% | 21.01% | 0.49x | 1.36x | NT$48.26 Million |
| 2011 | 10.36% | 16.91% | 0.47x | 1.31x | NT$4.50 Million |
| 2012 | 12.96% | 19.74% | 0.52x | 1.27x | NT$37.95 Million |
| 2013 | 13.32% | 22.47% | 0.48x | 1.24x | NT$53.63 Million |
| 2014 | 15.46% | 25.89% | 0.48x | 1.25x | NT$102.73 Million |
| 2015 | 16.64% | 25.07% | 0.50x | 1.32x | NT$126.00 Million |
| 2016 | 17.24% | 25.46% | 0.55x | 1.23x | NT$150.50 Million |
| 2017 | 14.22% | 21.40% | 0.54x | 1.23x | NT$90.26 Million |
| 2018 | 17.50% | 25.11% | 0.58x | 1.20x | NT$173.59 Million |
| 2019 | 18.66% | 24.97% | 0.63x | 1.18x | NT$215.36 Million |
| 2020 | 18.34% | 25.09% | 0.55x | 1.34x | NT$222.24 Million |
| 2021 | 15.38% | 23.62% | 0.47x | 1.38x | NT$150.94 Million |
| 2022 | 16.28% | 24.55% | 0.45x | 1.48x | NT$190.34 Million |
| 2023 | 14.19% | 23.27% | 0.42x | 1.45x | NT$133.54 Million |
| 2024 | 15.35% | 25.49% | 0.45x | 1.35x | NT$184.16 Million |
| 2025 | 14.95% | 25.25% | 0.46x | 1.29x | NT$178.47 Million |
Industry Comparison
This section compares Bioteque's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,086,258,444
- Average return on equity (ROE) among peers: 8.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bioteque (4107) | NT$3.61 Billion | 7.36% | 0.29x | $254.35 Million |
| St.Shine Optical Co Ltd (1565) | $6.27 Billion | 16.26% | 0.32x | $149.63 Million |
| Maxigen Biotech Inc (1783) | $851.32 Million | 7.06% | 0.39x | $108.92 Million |
| SciVision Biotech Inc (1786) | $894.21 Million | -2.94% | 0.52x | $127.07 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $56.65 Million |
| BenQ Medical Technology (4116) | $1.74 Billion | 10.38% | 0.96x | $52.93 Million |
| Pacific Hospital Supply Co Ltd (4126) | $1.64 Billion | 19.09% | 0.21x | $184.36 Million |
| Bionime Corp (4737) | $1.76 Billion | -10.27% | 2.25x | $136.84 Million |
| Vizionfocus Inc. (4771) | $2.02 Billion | 15.48% | 0.59x | $344.96 Million |
| Formosa Optical Technology Co Ltd (5312) | $2.38 Billion | 10.63% | 0.86x | $184.49 Million |
About Bioteque
Bioteque Corporation manufactures and sells medical devices in Asia, South America, North America, and internationally. The company offers angiography catheter, balloon dilation catheter, guiding sheath, guide steel wire, y-type connector, multi-pipe joint, connecting pipe, y-type connector assembly, peripheral vascular guiding catheter, coronary balloon dilation catheter, central venous catheter… Read more